Peptide Stacks for Research: BPC-157, TB-500, and Beyond
Combining research peptides — commonly called “stacking” in the research community — is the practice of using two or more peptides simultaneously to target complementary or synergistic biological pathways. The rationale is straightforward: most biological processes involve multiple molecular actors operating in parallel, and a single compound engaging one receptor or one pathway will rarely produce the same research output as compounds designed to address the same biological endpoint from multiple mechanistic angles. This guide covers the scientific basis for the most studied peptide combination protocols.
BPC-157 + TB-500: The Classic Tissue Repair Stack
The most widely discussed dual-peptide research combination is BPC-157 (CAS 137525-51-0) and TB-500 (Thymosin Beta-4 synthetic analog; CAS 77591-33-4). Both compounds promote angiogenesis and tissue repair, but via mechanistically distinct pathways that complement rather than duplicate each other.
BPC-157 drives tissue repair primarily through growth factor upregulation (VEGF, EGF, FGF) and the FAK-paxillin signaling cascade, which governs cell migration, adhesion, and extracellular matrix remodeling at wound sites. TB-500’s active region (the LKKTET motif) functions through actin sequestration — binding G-actin monomers and regulating the actin cytoskeleton to enhance cell motility and promote migration of endothelial cells and keratinocytes to sites of injury.
The mechanistic logic: BPC-157 establishes the growth factor microenvironment and signaling scaffold; TB-500 physically mobilizes the cells that need to populate the repair site. Combat Research supplies a pre-formulated BPC-157 + TB-500 blend for researchers working with this combination.
GLP-1 + Amylin (CagriSema Model): The Dual Metabolic Stack
The GLP-1 + amylin receptor combination is the biological basis for Novo Nordisk’s CagriSema program. In research contexts, combining a GLP-1R agonist (semaglutide) with a long-acting amylin analog (cagrilintide) enables simultaneous investigation of two distinct satiety signaling systems:
- GLP-1R: hypothalamic ARC/PVN and brainstem NTS circuits → insulin-focused satiety
- AMY1-3R: area postrema, lateral parabrachial nucleus, central amygdala → aversive/hedonic satiety
Phase 2 and Phase 3 data from Novo Nordisk demonstrate this is not additive but synergistic — the dual-pathway combination produces greater metabolic research outcomes than doubling the dose of either monotherapy. Combat Research’s Cagrilintide/GLP-1 5mg/5mg blend provides both components in a single vial for this research application.
GHRH + GHS: The Pulsatile Growth Hormone Stack
A third well-characterized research combination targets the growth hormone secretagogue axis by combining a GHRH analog with a separate GHS-R1a agonist:
- GHRH analog (Sermorelin or CJC-1295 No DAC) — stimulates somatotrophs to synthesize and release GH via GHRHR activation
- GHS-R1a agonist (Ipamorelin) — independently triggers GH pulse via the ghrelin receptor, without the cortisol and prolactin elevation seen with older GHRP compounds
The combination produces synergistic GH pulse amplitude compared to either agent alone, because the two compounds act on different receptors on the same somatotroph cell. Sermorelin provides the GHRH signal (more GH synthesis); Ipamorelin amplifies the pulsatile release. This combination is distinct from CJC-1295 with DAC, which uses albumin binding for a sustained GH elevation profile rather than a pulsatile one.
MOTS-C + Metabolic Compounds: Mitochondrial + Receptor Dual-Targeting
MOTS-C activates AMPK via the folate/AICAR pathway — an endogenous mitochondrial mechanism. Combining MOTS-C with receptor-level metabolic compounds (GLP-1 agonists, insulin sensitizers) targets metabolic regulation at two distinct levels simultaneously: the intracellular bioenergetic/AMPK layer (MOTS-C) and the cell-surface receptor/hormone signaling layer (GLP peptides). This multi-level approach is increasingly common in longevity and metabolic research protocols.
Frequently Asked Questions — Peptide Stacks
Why combine peptides instead of using higher doses of one?
Because most complex biological processes involve multiple converging pathways. Escalating the dose of a single compound produces more activity at its specific receptor but doesn’t engage complementary mechanisms. Combining mechanistically distinct compounds covers more of the biology relevant to the research endpoint.
Does combining peptides introduce additional complexity for research design?
Yes. Multi-compound protocols require careful experimental design to attribute observed effects to individual components, identify additive vs. synergistic contributions, and account for potential pharmacokinetic interactions. Researchers should design combination protocols with appropriate single-compound control arms.
Which Combat Research products are available as pre-formulated blends?
Combat Research currently offers a BPC-157 + TB-500 blend and a Cagrilintide / Semaglutide (GLP-1) 5mg/5mg blend as pre-formulated dual-peptide research products. All other combination protocols can be constructed from individual single-compound products.
